JANUMET
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1,103 | 28 | 0 |
| 2023 | $2,628 | 83 | 55 |
| 2022 | $2,850 | 20 | 18 |
| 2021 | $27,956 | 55 | 18 |
| 2020 | $16,776 | 62 | 43 |
| 2019 | $72,569 | 243 | 195 |
| 2018 | $382,808 | 989 | 710 |
| 2017 | $443,387 | 7,407 | 3,798 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $646,383 | 459 | 68.0% |
| Food and Beverage | $148,708 | 8,281 | 15.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $123,585 | 74 | 13.0% |
| Consulting Fee | $22,609 | 18 | 2.4% |
| Travel and Lodging | $8,790 | 55 | 0.9% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase III Multicenter, Double-Blind, Randomized Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR a Fixed-Dose Combination Tablet of Sitagliptin and Extended-Release Metformin in Pediatric Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin Therapy Alone or in Combination with Insulin | Merck Sharp & Dohme Corporation | $384,637 | 1 |
| A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trialto Evaluate the Safety and Efficacy MK-0431A A Fixed-Dose Combination Tablet ofSitagliptin and Metformin in Pediatric Patients with Type 2 Diabetes Mellitus WithInadequate Glycemic Control on Metformin Therapy Alone or in Combination withInsulin | Merck Sharp & Dohme Corporation | $237,885 | 0 |
| A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy MK-0431A A Fixed-Dose Combination Tablet of Sitagliptin and Metformin in Pediatric Patients with Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy Alone or in Combination with Insulin | Merck Sharp & Dohme Corporation | $18,733 | 0 |
| A Phase III Multicenter, Double-Blind, Randomized Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR a Fixed-Dose Combination Tablet of Sitagliptin and Extended-Release Metformin in Pediatric Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin Therapy Alone or in Combination with Insulin | Merck Sharp & Dohme LLC | $2,628 | 0 |
| A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy MK-0431A A Fixed-Dose Combination Tablet of Sitagliptin and Metformin in Pediatric Patients with Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy Alone or in Combination with Insulin | Merck Sharp & Dohme LLC | $2,500 | 0 |
Manufacturing Companies
- Merck Sharp & Dohme Corporation $943,495
- Merck Sharp & Dohme LLC $6,580
Product Information
- Type Drug
- Total Payments $950,076
- Total Doctors 4,627
- Transactions 8,887
About JANUMET
JANUMET is a drug associated with $950,076 in payments to 4,627 healthcare providers, recorded across 8,887 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2024. In 2024, $1,103 was paid across 28 transactions to 0 doctors.
The most common payment nature for JANUMET is "Unspecified" ($646,383, 68.0% of total).
JANUMET is associated with 5 research studies, including "A Phase III Multicenter, Double-Blind, Randomized Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR a Fixed-Dose Combination Tablet of Sitagliptin and Extended-Release Metformin in Pediatric Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin Therapy Alone or in Combination with Insulin" ($384,637).